Session Chair Profile

Ph.D., Vice Chancellor for Science Policy and Strategy, UCSF; Director, UCSF Precision Medicine; Professor, Cellular & Molecular Pharmacology, UCSF

Biography
Dr. Yamamoto is a leader in science and public policy. He has made an indelible impact by simultaneously advocating for Precision Medicine across the .edu, .gov, .com and .org sectors. As Chair of the National Academies Board on Life Sciences, he appointed and served on the study committee that produced “Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease”, the report that enunciated the precision medicine concept. He helped to stimulate President Obama’s interest, which led to the Precision Medicine Initiative, as well as Gov. Jerry Brown’s launch of the California Initiative to Advance Precision Medicine. He also promoted a precision medicine approach to Vice President Biden’s Cancer Moonshot, provoked broader participation by the corporate and nonprofit sectors, and directs UCSF Precision Medicine, an institution-wide imperative. In addition, Dr. Yamamoto has led or served on numerous federal or national committees focused on public and science policy, public understanding and support of biological research, research funding and peer review, and science education and the biomedical workforce; he chairs the Coalition for the Life Sciences, and sits on the National Academy of Medicine Council and Executive Committee, and the National Academy of Sciences Division of Earth and Life Studies Advisory Committee. He is a member of the Advisory Board for Lawrence Berkeley National Laboratory and the Board of Directors and Executive Committee of Research!America. At UCSF, Dr. Yamamoto is vice chancellor for science policy and strategy and professor of cellular and molecular pharmacology. He is a leading researcher, investigating transcriptional regulation by nuclear receptors, which mediate the actions of essential hormones and cellular signals; he uses mechanistic and systems approaches to pursue these problems in pure molecules, cells and whole organisms. He is an elected member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences, and the American Academy of Microbiology, and a fellow of the American Association for the Advancement of Science.


 Session Abstract – PMWC 2023 Silicon Valley


Track 4, January 25

Track Chair: TBA

  • How New Public-private Partnerships can Catalyze Transformative Health Breakthroughs
    Chair: Keith Yamamoto, UCSF
  • How New Public-private Partnerships can Catalyze Transformative Health Breakthroughs
  • Moving Sequencing into the Clinical Setting
    Chair: Charles Chiu, UCSF
    - Charlotte Hobbs, Rady Children’s Hospital
    - Euan Ashley, Stanford University
    - Sivan Bercovici, Karius
    - Heike Sichtig, Foundation Medicne
  • Evolving Sequencing Applications
    Chair: Cindy Lawley, Olink
  • Single-cell, Spatial, and in Situ Technologies
    Chair: Dina Finan, 10x Genomics
  • Spatial Single-Cell Multi-Omics
    Chair: TBA, NanoString
  • Perturb-seq for Genome-wide Single Cell RNA Sequencing
    Chair: TBA, Ultima
  • Combining WGS with a AI-based Tumor Enrichment Method
  • Multi-omics Approaches Supporting Clinical Translation

 Session Abstract – PMWC 2023 Silicon Valley


Track Chair:
Keith Yamamoto, UCSF

Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support

Sessions: